Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2INTERVENTIONAL

Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months

Who May Be Eligible (Plain English)

Who May Qualify: - osteoporosis patients Who Should NOT Join This Trial: - not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * osteoporosis patients Exclusion Criteria: * not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant

Treatments Being Tested

DRUG

SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"

To examine the effects of SERM and ELD in osteoporosis patients

DRUG

Bisphosphonates and ELD "Edirol®Tablet 0.75ug"

To examine the effects of BP and ELD in osteoporosis patients

DRUG

ELD "Edirol®Tablet 0.75ug"

To examine the effects of ELD in osteoporosis patients

Locations (1)

Yukio Nakamura
Matsumoto, Nagano, Japan